These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12522573)

  • 61. Which factors influence therapeutic decisions in Parkinson's disease?
    Baas H; Fuchs G; Gemende I; Hueber R; Lachenmayer L; Schneider E; Schoenberger B; Werner M
    J Neurol; 2002 Oct; 249 Suppl 3():III/49-52. PubMed ID: 12522573
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dyskinesia in Parkinson's disease. Pathophysiology and clinical risk factors.
    Baas H
    J Neurol; 2000 Sep; 247 Suppl 4():IV/12-6. PubMed ID: 11199809
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatments for Parkinson disease--past achievements and current clinical needs.
    Poewe W
    Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
    [TBL] [Abstract][Full Text] [Related]  

  • 65. New drugs in the future treatment of Parkinson's disease.
    Djaldetti R; Melamed E
    J Neurol; 2002 Sep; 249 Suppl 2():II30-5. PubMed ID: 12375061
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Dyskinesia in Parkinson's disease--major clinical features, aetiology, therapy].
    Ellrichmann G; Russ H; Müller T
    Fortschr Neurol Psychiatr; 2007 Jul; 75(7):387-96. PubMed ID: 17443441
    [TBL] [Abstract][Full Text] [Related]  

  • 69. An update on the treatment of Parkinson's disease.
    Jankovic J
    Mt Sinai J Med; 2006 Jul; 73(4):682-9. PubMed ID: 16878274
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Parkinson's disease: diagnosis and treatment.
    Rao SS; Hofmann LA; Shakil A
    Am Fam Physician; 2006 Dec; 74(12):2046-54. PubMed ID: 17186710
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease.
    Koutsilieri E; Riederer P
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S329-31. PubMed ID: 18267259
    [TBL] [Abstract][Full Text] [Related]  

  • 72. When and how should treatment be started in Parkinson disease?
    Lang AE
    Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
    Hallett PJ; Standaert DG
    Pharmacol Ther; 2004 May; 102(2):155-74. PubMed ID: 15163596
    [TBL] [Abstract][Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.